Technology Networks: Driving Drug Discovery Success With Synthetic Biology and NGS

Last month, A-Alpha Bio’s CEO David Younger had a Q&A session with Technology Networks’s Laura Elizabeth Lansdowne to discuss how the company’s ability to harness synthetic biology and next generation sequencing can identify millions of protein-protein interactions.